Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis
Yici Yan, Zhenyi Lin, Jing Yuan, Weidong Gao, Chenxu Jiao, Leitao Sun, Xun Sun · 2026
Read Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis by Yici Yan, Zhenyi Lin, Jing Yuan, Weidong Gao, Chenxu Jiao, Leitao Sun, Xun Sun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272484.txt.
Description
Yici Yan and colleagues reviewed cetuximab maintenance treatment for metastatic colorectal cancer in a 2026 meta-analysis. Cetuximab is an antibody drug used after first treatment, and doctors disagree on whether patients should keep taking it. The review pooled survival and safety results from prior studies.
Six studies with 727 patients met the selection rules after searches of four databases. Patients who stayed on cetuximab lived longer without their cancer growing, and they also lived longer overall. Asian patients seemed to gain more than other groups. Rash and diarrhea were more common with the drug, though overall harm rates did not differ clearly. The authors call for larger trials to confirm these gains.
Catalog record
| CREATOR | Yici Yan, Zhenyi Lin, Jing Yuan, Weidong Gao, Chenxu Jiao, Leitao Sun, Xun Sun |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |